Q1 2019 13F Holdings Report, New Holdings, Stock Holdings
Signature - Title
Oshrat Levi - Chief Financial Officer
Location
Tel Aviv, Israel
Holdings as of
March 31, 2019
Value $
$0
Num holdings
2
Date filed
6/20/2019, 07:37 AM
Description
The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
Our algorithm has found invalid data in this filing
Sym
Weight
Trade Impact
Company
Class
Shares Change
Activity
Value Change $
Value $
* Price $
Shares
Principal
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Israel Mor
Partner
Tel Aviv, Israel
6/20/2019
This Form 13F/A is filed as an amendment to the Form 13F filed on May 7, 2019 (the "Original 13F Q1/2019 Filing"), to add new holdings entries which were unintentionally omitted from the Original Q1/2019 13F Filing, which otherwise remains unchanged. Investment discretion with regard to a portion of the securities reported herein is exercised by Sphera Global Healthcare Management L.P. (the "Management Company"). The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd. (the "General Partner"), the shares of which are owned 50% by Sphera Funds Management Ltd. ("SFML"). SFML is entitled to appoint 50% of the members of the board of directors of the General Partner (the "Board of Directors") and 50% of the members to the investment committee of the Management Company (the "Investment Committee"), and therefore may be deemed to share control of the General Partner and Management Company. This Form 13F shall not be construed as an admission by SFML, the General Partner, or the Management Company that it is the beneficial owner of any of the securities covered by this Form 13F, and each of SFML, the General Partner, and the Management Company disclaim beneficial ownership of any such securities. Per informal guidance received from the Division of Investment Management, section 13(f) securities that are dual listed on a U.S. stock exchange and the Tel Aviv Stock Exchange were included in this Form 13F only if they were purchased in the U.S.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.